Why the study?
Data are lacking regarding the optimal timing of COVID-19 vaccinations for people living with multiple sclerosis, while delaying disease-modifying therapies may increase the risk of disease activity and progression.
Expert consensus recommends that patients with multiple sclerosis receive COVID-19 vaccination as soon as possible, prioritizing vaccination over the timing of disease-modifying therapies.
Supports prioritizing COVID-19 vaccination in MS regardless of DMT; leaves open need for prospective confirmation.
COVID-19 vaccines are safe for people living with MS on or off disease-modifying therapies and are important for the prevention of COVID-19. Antibody responses for individuals on certain DMTs may be diminished, however, T-cell responses may be preserved in those individuals. Data are lacking regarding optimal timing of vaccinations, and delaying disease-modifying therapies may increase the risk of disease activity and progression. In this perspective podcast, the authors recommend COVID-19 vaccination as soon as possible, regardless of timing considerations, in most cases.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: